CXCL10-expressing Oncolytic Vaccinia Virus Western Reserve (ΔE3L), pSL-CXCL10(Cat#: CyOV-0010WQ)

This product is a CXCL10 expressing oncolytic vaccinia virus, which is based on VACV-WR with E3L deleted. Binding of CXCL10 to CXCR3 results in pleiotropic effects, including stimulation of monocytes, natural killer and T-cell migration, and modulation of adhesion molecule expression. The deletion of E3L and CXCL10 expression could enhance the immune activity. This product can be used in oncolytic virotherapy research and vaccinie application.

Specifications

Family Poxviridae
Species Vaccinia virus
Serotype Western Reserve
Backbone VACV-WR(ΔE3L)
Backbone Background VACV-WR strain derived from Wyeth through passaging in mice and shown high tumor selectivity and strong oncolytic effect in mouse models.The engineered VACV-WR could further enhance the immune activity and the efficacy of cancer therapies.
Gene Modification ΔE3L
Promoter pSL
Transgene CXCL10
Type of Transgene Cytokine
Related Target/Protein C-X-C motif chemokine ligand 10
Capsid Modification None
Titer >1*10^8 PFU
Related Diseases Mammary tumor

Transgene

Alternative Names C7; IFI10; INP10; IP-10; crg-2; mob-1; SCYB10; gIP-10
Gene ID 3631
UniProt ID P02782

Information

Introduction This antimicrobial gene encodes a chemokine of the CXC subfamily and ligand for the receptor CXCR3. Binding of this protein to CXCR3 results in pleiotropic effects, including stimulation of monocytes, natural killer and T-cell migration, and modulation of adhesion molecule expression.

Customer Reviews and Q&As

There are currently no customer reviews or questions for CXCL10-expressing Oncolytic Vaccinia Virus Western Reserve (ΔE3L), pSL-CXCL10 (CyOV-0010WQ). Click the button below to contact us or submit your feedback about this product.

All products and services are for Research Use Only. Not For Clinical Use.

Other products

PRODUCTS

Online Inquiry